Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis
May 18 2021 - 8:05AM
Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical
company pioneering differentiated therapies for patients with liver
and gastrointestinal diseases, today announced it has enrolled the
first 60 patients in its MET642 Phase 2a trial. The Company remains
on track to report interim results in the fourth quarter of 2021
after these patients have completed 16 weeks of
treatment.
“The promise of an optimized FXR agonist has motivated
investigators, and most importantly patients, to participate in our
study,” said Hubert C. Chen, M.D., chief medical officer,
Metacrine. “We are grateful for their enthusiasm and support in
reaching this important milestone, as well as for the hard work of
our clinical operations team in a challenging Covid-19
environment.”
The Phase 2a study (NCT04773964) is a 16-week, randomized,
placebo-controlled, multi-center trial evaluating the safety,
tolerability and pharmacological activity (as measured by liver fat
reduction) of MET642 (3 mg and 6 mg). Full topline trial results of
up to 180 patients are expected to be reported in the first half of
2022.
About Metacrine
Metacrine, Inc. is a clinical-stage biopharmaceutical company
building a pipeline of differentiated therapies to treat liver and
gastrointestinal diseases. Metacrine has developed a
proprietary farnesoid X receptor (FXR) platform utilizing a unique
chemical scaffold, which has demonstrated an improved therapeutic
profile in clinical trials. The Company’s two product
candidates, MET409 and MET642, are currently being investigated in
clinical trials as potential new treatments for NASH.
MET409 has completed a 12-week monotherapy trial in patients with
NASH and is being evaluated in a 12-week combination trial with
empagliflozin in patients with both NASH and type 2
diabetes. MET642 has completed a 14-day Phase 1 trial
in healthy volunteers and is being evaluated in a 16-week
monotherapy trial in patients with NASH. To learn more,
visit www.metacrine.com.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements in
this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, statements about the design, progress,
timing, scope and results of clinical trials; the anticipated
timing of disclosure of results of clinical trials; statements
regarding the therapeutic potential of MET409 and MET642; the
differentiated nature of Metacrine’s FXR program; . Words such as
“may,” “will,” “expect,” “plan,” “aim,” “projected,” “likely,
”anticipate,” “estimate,” “intend,” “potential,” “prepare,”
“perceived,” “believes” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Metacrine’s
expectations and assumptions that may never materialize or prove to
be incorrect. Each of these forward-looking statements involves
risks and uncertainties. Actual results may differ materially from
those projected in any forward-looking statements due to numerous
risks and uncertainties, including but not limited to: risks and
uncertainties regarding regulatory approvals for MET409 or MET642;
potential delays in initiating, enrolling or completing any
clinical trials; potential adverse side effects or other safety
risks associated with Metacrine’s product candidates; competition
from third parties that are developing products for similar uses;
and Metacrine’s ability to obtain, maintain and protect its
intellectual property. Information regarding the foregoing and
additional risks may be found in the section entitled “Risk
Factors” in Metacrine’s Annual Report on Form 10-K filed with the
Securities and Exchange Commission (the “SEC”) on March 18, 2021,
and in Metacrine’s other filings with the SEC. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Except as required by law, Metacrine
assumes no obligation to update any forward-looking statements
contained herein to reflect any change in expectations, even as new
information becomes available.
Investor & Media Contact
Steve Kunszabo
Metacrine, Inc.
+1 (858) 369-7892
skunszabo@metacrine.com
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Sep 2023 to Sep 2024